Zenith Capital (TSXV:ZENI.P) EV-to-EBIT : -0.93 (As of May. 30, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zenith Capital's Enterprise Value is C$20.15 Mil. Zenith Capital's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was C$-21.65 Mil. Therefore, Zenith Capital's EV-to-EBIT for today is -0.93.

The historical rank and industry rank for Zenith Capital's EV-to-EBIT or its related term are showing as below:

TSXV:ZENI.P' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.22 Med: 0 Max: 0.1
Current: -0.93

During the past 6 years, the highest EV-to-EBIT of Zenith Capital was 0.10. The lowest was -4.22. And the median was 0.00.

TSXV:ZENI.P's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 10.01 vs TSXV:ZENI.P: -0.93

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Zenith Capital's Enterprise Value for the quarter that ended in Jan. 2024 was C$27.45 Mil. Zenith Capital's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was C$-21.65 Mil. Zenith Capital's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was -78.87%.

Zenith Capital EV-to-EBIT Historical Data

The historical data trend for Zenith Capital's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital EV-to-EBIT Chart

Zenith Capital Annual Data

Trend

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

EV-to-EBIT

Get a 7-Day Free Trial

-1.81

-4.40

-2.48

-1.25

Zenith Capital Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EV-to-EBIT	Get a 7-Day Free Trial															-2.85	-1.25	-1.11	-1.15	-1.27

Competitive Comparison of Zenith Capital's EV-to-EBIT

For the Biotechnology subindustry, Zenith Capital's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zenith Capital's EV-to-EBIT falls into.

Zenith Capital EV-to-EBIT Calculation

Zenith Capital's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	20.145	/	-21.651
	=	-0.93

Zenith Capital's current Enterprise Value is C$20.15 Mil.
Zenith Capital's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-21.65 Mil.

Zenith Capital (TSXV:ZENI.P) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Zenith Capital's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jan. 2024 )	=	EBIT	/	Enterprise Value (Q: Jan. 2024 )
	=	-21.651	/	27.453105
	=	-78.87 %

Zenith Capital's Enterprise Value for the quarter that ended in Jan. 2024 was C$27.45 Mil.
Zenith Capital's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-21.65 Mil.

Zenith Capital EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Zenith Capital's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (TSXV:ZENI.P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corporation (TSXV:ZENI.P) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2475 Queens Avenue, West Vancouver, BC, CAN, V7V 2Y9

Website

https://www.zenithepigenetics.com

Zenith Capital Corporation is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical needs. The company is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for mCRPC in combination with androgen receptor inhibitor, XTANDI, with Astellas and Newsoara as collaborators; triple-negative breast cancer in combination with the PARP inhibitor TALZENNA with Pfizer as a collaborator; androgen receptor independent mCRPC in combination with immune checkpoint inhibitor KEYTRUDA and XTANDI with University of California, San Francisco as a collaborator.

Zenith Capital (TSXV:ZENI.P) Headlines

No Headlines